本文来自彭博终端，终端用户可运行NSN T06LY9GPFHVK 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 全球市场版图日新月异，彭博行业研究（Bloomberg Intelligence）为您的企业战略助力。在 制药与生物技术领域，无论是全球行业资讯与热点，还是制药管线里程碑及催化剂事件、财务 预测…… BI涵盖广泛且深度的关键信息，旨在为您的决策提供可靠且具有竞争力的洞见支撑。 扫描二维码 立即订阅 彭博生物制药双周报 根据彭博行业研究的专有数据库，上半年授权交易数量（剔除联合试验）持续下滑，总计 2 4 1宗，为六年来最低水平。同期，大型药企签订了5 2宗交易，与过去两年的低迷水平持 平。交易放缓的主要原因是强生、葛兰素史克、默克与诺华的交易减少。强生将其重心转向 并购，而默克则仍相对不活跃。 上半年，礼来和阿斯利康分别以11宗和8宗交易领跑。礼来的交易范围涵盖中枢神经系统、 心血管代谢等疾病领域，其中1 0宗交易处于临床前阶段。阿斯利康则专注于癌症（4宗）和 免疫领域（4宗）。预付款金额最大（1 6 . 5亿美元）的交易是罗氏与Ze a l a n d Ph a rma达成的 协议。 ...

New Drug Development - Eli Lilly's oral GLP-1 drug trial shows potential for a pill form of GLP-1 medication, offering an alternative to injectables [1] - The oral GLP-1 drug is a small molecule absorbed in the stomach, allowing for daily intake instead of weekly injections [3] - Clinical trials indicate that approximately 40% of patients at the highest dose experienced weight loss greater than 15% [5] - The most significant side effect observed with the pill is nausea, similar to other GLP-1 medications [4] - The industry hopes the pill's easier manufacturing and lack of refrigeration needs will lead to significantly lower costs [12] - The industry anticipates potential FDA fast-track approval, possibly leading to market availability sometime next year [15][16] Obesity and GLP-1 - The medical community is shifting away from viewing obesity as a moral failing towards recognizing it as a chronic disease requiring long-term treatment [7][8][9] - GLP-1 medications can help patients overcome the body's natural resistance to weight loss by influencing hormones and reducing the urge to overeat [10][11] - GLP-1 activation may have anti-inflammatory benefits and could potentially improve conditions like autoimmune diseases, psoriasis, and potentially reduce the risk of dementia [13][14] - Over 50% of Americans are considered in the obese range, highlighting the potential impact of accessible treatments on cardiovascular disease and related health issues [12]

瑞银将礼来的目标价从1050美元下调至895美元，仍维持"买入"评级。(格隆汇) ...

摩根大通发表报告指，礼来在第二季财报公布后，是该行在美国大型生技制药股中首选标的。分析师写 道，虽然orforglipron在肥胖症减重的第三期试验数据略低于预期，仍认为该产品在市场中有明确定位， 同时礼来的核心可注射incretin药物系列依然处于最佳竞争位置。他们补充称，在上周股价回档之后， 礼来目前本益比仅约为2025年每股盈余预估值的29倍，以及2026年每股盈余预估值的21倍，且这些为保 守预估值。 ...

Market Overview - Major U.S. stock indices experienced a collective decline, with the Dow Jones Industrial Average falling by 200.52 points (0.45%) to close at 43,975.09 points, the Nasdaq down by 64.62 points (0.30%) at 21,385.40 points, and the S&P 500 decreasing by 16.00 points (0.25%) to 6,373.45 points [1] - Large-cap tech stocks mostly declined, with Apple down 0.83%, Amazon down 0.62%, Facebook down 0.45%, Nvidia down 0.3%, Google down 0.21%, and Microsoft down 0.02% [3][4] Notable Stock Movements - Tesla saw an increase of nearly 3%, marking its fourth consecutive day of gains [3] - Fannie Mae rose over 15% and Freddie Mac increased by more than 13%, both reaching their highest closing levels since 2008 [3] Sector Performance - Bank stocks showed mixed results, with Morgan Stanley up 0.53%, Bank of America up 0.38%, and JPMorgan up 0.32%. Conversely, Citigroup fell by 0.44%, Goldman Sachs down 0.24%, and Wells Fargo down 0.31% [5] - Gold stocks generally declined, with Harmony Gold, Eldorado Gold, and AngloGold down over 1%, and Coeur Mining down 0.3% [5] Chinese Stocks - The Nasdaq Golden Dragon China Index fell by 0.29%, with individual stocks showing mixed performance. Xpeng Motors rose nearly 6%, Tencent Music up over 2%, while NIO, Bilibili, and Xiaoma Zhixing increased by over 1%. On the downside, WeRide fell over 4%, TAL Education down more than 3%, and Li Auto down nearly 3% [6] Commodity Prices - The FTSE A50 futures index fell by 0.32% to 13,881 points [9] - Crude oil prices saw slight increases, with WTI crude up by 8 cents to $63.96 per barrel (0.13% increase) and Brent crude up by 4 cents to $66.63 per barrel (0.06% increase) [9] - Gold futures dropped by 2.78% to $3,394.1 per ounce, while silver futures fell by 2.29% to $37.66 per ounce [10] Currency Exchange - The offshore RMB (CNH) against the USD was reported at 7.1965, a decrease of 72 points from the previous Friday's close [11] Economic Indicators - Attention is focused on upcoming U.S. inflation data, particularly the Consumer Price Index (CPI) for July, which is expected to provide insights into the impact of tariffs on consumer prices [12][13]

周一，美国科技股七巨头指数跌0.25%，报188.78点。苹果收跌0.83%，亚马逊跌0.62%，Meta Platforms、英伟达、谷歌A、微软至多跌0.35%，特斯拉涨2.85%——该公司申请向英国家庭供电。此 外，AMD收跌0.28%，伯克希尔哈撒韦B类股跌0.14%，台积电ADR则收涨0.11%，礼来制药涨1.53%。 本文源自：金融界AI电报 ...

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [2][5] - The competition among pharmaceutical giants is intensifying, particularly in the GLP-1 category, with Novo Nordisk and Eli Lilly leading the charge [5][6] Group 1: GLP-1 Drug Market - GLP-1 drugs are the main drivers of market growth, contributing nearly 30% to the global biopharmaceutical market [3][5] - Semaglutide from Novo Nordisk topped the sales chart with $16.632 billion, while Eli Lilly's tirzepatide followed closely with $14.734 billion, marking a significant year-on-year growth of 121.3% [5][6] - The competitive landscape is shifting, with semaglutide's various formulations (injection, oral, and weight loss) ending Keytruda's long-standing dominance [5][6] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the top-selling drugs [3][10] - ADC drug Enhertu made its debut in the top rankings with $3.9 billion in sales, indicating a growing interest in innovative therapies [3][10] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis' Ribociclib showed a remarkable growth rate of 58.7% [10] - Pfizer's Palbociclib, once a market leader, has seen a decline, dropping to $2.026 billion in sales [10] Group 4: BTK Inhibitors - The BTK inhibitor market is projected to reach approximately $12.5 billion by 2024, with Ibrutinib, Zebrutinib, and Acalabrutinib dominating the market [11][12] - Zebrutinib from BeiGene has entered the global top 50 list with $1.742 billion in sales, marking a significant achievement for Chinese innovation in the pharmaceutical sector [12][13]

智通财经APP获悉，周一，礼来(LLY.US)股价走高，截至发稿，该股涨3.8%，报649.66美元。消息面 上，德意志银行分析师James Shin维持礼来"买入"评级，但下调目标价至900美元。富瑞集团分析师 Akash Tewari、摩根士丹利分析师Terence Flynn、摩根大通分析师Chris Schott、花旗分析师Geoff Meacham、Truist Financial分析师Srikripa Devarakonda同样维持该股"买入"评级。 ...

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [1][6][13] - The competition among global pharmaceutical giants is intensifying, particularly in the metabolic drug sector, with companies like Novo Nordisk and Eli Lilly expected to expand their advantages [2][4] Group 1: GLP-1 Drug Market - GLP-1 drugs are leading the market, with Novo Nordisk's semaglutide family generating $16.632 billion in sales, marking its first position in the ranking [6] - Eli Lilly's tirzepatide follows closely with $14.734 billion in sales, showing a remarkable year-on-year growth of 121.3% [6] - The sales dynamics indicate that semaglutide's injection version holds a 61% market share, while the oral version accounts for 29% [6][7] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the market [1][13] - ADC drug Enhertu has entered the top rankings with $3.9 billion in sales [1] - mRNA vaccines have collectively contributed $9.4 billion, showcasing the impact of innovative therapies in the pharmaceutical landscape [1] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis's Ribociclib has surged with a 58.7% growth [10][11] - Pfizer's Palbociclib has seen a decline, dropping to $2.026 billion, marking a significant shift in market dynamics [11] Group 4: Chinese Pharmaceutical Innovations - The entry of Chinese innovation, specifically BeiGene's Zebrutinib, into the global top 50 with $1.742 billion in sales signifies a breakthrough for domestic drugs [12] - Zebrutinib's success reflects the potential for Chinese pharmaceuticals to transition from thematic investments to performance-driven investments in the global market [12]

Core Insights - The global obesity market is primarily dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with LLY's Zepbound and NVO's Wegovy as leading GLP-1 injectable therapies. Zepbound has shown rapid sales growth, surpassing Wegovy in weight-loss efficacy in clinical studies [1][3] - In the first half of 2025, Zepbound generated $5.69 billion in revenues, prompting LLY to raise its full-year sales guidance to $60-$62 billion. In contrast, Wegovy recorded $5.41 billion in sales during the same period, leading Novo Nordisk to revise its sales outlook downward due to increased competition [2][8] - LLY faced a setback with its oral GLP-1 candidate, orforglipron, which did not meet investor expectations in weight-loss efficacy, resulting in an 18.6% decline in LLY shares. This has shifted market confidence towards Novo Nordisk, which saw a 4.7% increase in its stock [3][4] Company Performance - LLY's stock has underperformed, losing 19% year-to-date compared to an 8.3% decline in the industry. The stock is trading at a price/earnings ratio of 22.85, higher than the industry average of 13.71, but below its five-year mean of 34.54 [7][11] - Estimates for LLY's 2025 earnings have improved from $21.92 to $22.11 per share, while estimates for 2026 earnings have slightly declined from $30.84 to $30.74 [16] Market Developments - The setback with orforglipron has shifted focus towards oral obesity treatment options, which could enhance patient adherence. Novo Nordisk is seeking FDA approval for a 25 mg oral semaglutide, with a decision expected by year-end [5][8] - Other companies, such as Viking Therapeutics, are also advancing in the development of GLP-1-based obesity treatments, with ongoing studies for their investigational drug VK2735 [6]